Search

Introduction: Nasopharyngeal carcinomas represent a public health problem in southeast of Asia and in North Africa; the UCNT is the most found histological type. Its treatment is based on radiation therapy, with or without concomitant chemotherapy. We report in this study the efficacy and the safety of induction chemotherapy in nasopharyngeal cancers. Methods: A retrospective study of nasopharyngeal carcinomas received induction chemotherapy at the medical oncology department of the university hospital of Blida (Algeria) from 2014 to 2015. Results: Thirty-tow (32) patients were included (24 men/8 women), with a median age of 48.5 years (range 18 - 75) and a performance status (PS) 0/1. The main symptom was cervical lymphadenopathies (62.5%). 46.8% of patients were at Stage IV, with only 3 patients (9.4%) with M1 disease. An average of 4.13 cycles of induction chemotherapy were given [IC95% 3.86 - 4.59], with 90.625% of XP regimen protocol (Cisplatin 75mg/m? IV day 1 + Capecitabine 1000mg/m? PO BiD, from day 1 to day 14; 21 day cycles). The evaluation found an objective response rate of 84.3%, including a partial remission ( ) in 62.5% of patients, a stable disease (SD) in 21.8%. progressive disease was found in 15.6% of patients. The grade 3/4 hematological toxicities included neutropenia (18.7% of patients), anemia (3.12%) and thrombocytopenia (3.12%). The grade 3/4 non-hematologic toxicities included nausea and vomiting (28.12%). No treatment discontinuation due to treatment toxicity was found. Conclusion: Induction chemotherapy with XP regimen in nasopharyngeal carcinoma is an interesting one day hospitalization regimen. It's an alternative option that may allow obtaining objective response rates of 85%, with manageable toxicities. [ABSTRACT FROM AUTHOR]